(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 34.21% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.66%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.63%.
Mirum Pharmaceuticals's revenue in 2025 is $307,028,000.On average, 5 Wall Street analysts forecast MIRM's revenue for 2025 to be $20,726,650,343, with the lowest MIRM revenue forecast at $19,442,959,815, and the highest MIRM revenue forecast at $23,686,900,896. On average, 4 Wall Street analysts forecast MIRM's revenue for 2026 to be $26,523,203,619, with the lowest MIRM revenue forecast at $22,726,665,243, and the highest MIRM revenue forecast at $33,586,405,796.
In 2027, MIRM is forecast to generate $37,009,372,516 in revenue, with the lowest revenue forecast at $30,525,633,648 and the highest revenue forecast at $43,493,111,384.